<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?npg-journal-abbreviation?><?properties open_access?><?DTDIdentifier.IdentifierValue -//NPGSJ//DTD full length article DTD version 7.0 XML//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ajarticle_v7_x.dtd?><?SourceDTD.Version 7.0?><?ConverterInfo.XSLTName naturesa2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutr Diabetes</journal-id><journal-id journal-id-type="iso-abbrev">Nutr Diabetes</journal-id><journal-title-group><journal-title>Nutrition &amp; Diabetes</journal-title></journal-title-group><issn pub-type="epub">2044-4052</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5022149</article-id><article-id pub-id-type="pii">nutd201637</article-id><article-id pub-id-type="doi">10.1038/nutd.2016.37</article-id><article-id pub-id-type="pmid">27571249</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running">Long-term effect of metformin in adolescents with obesity</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van der Aa</surname><given-names>M P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Elst</surname><given-names>M A J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>van de Garde</surname><given-names>E M W</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>van Mil</surname><given-names>E G A H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Knibbe</surname><given-names>C A J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>van der Vorst</surname><given-names>M M J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Pediatrics, St Antonius Hospital</institution>, Nieuwegein, <country>The Netherlands</country></aff><aff id="aff2"><label>2</label><institution>Department of Clinical Pharmacy, St Antonius Hospital</institution>, Nieuwegein, <country>The Netherlands</country></aff><aff id="aff3"><label>3</label><institution>Department of Pediatrics, Jeroen Bosch Hospital</institution>, ‘s-Hertogenbosch, <country>The Netherlands</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label><institution>Department of Pediatrics, St Antonius Hospital</institution>, PO Box 2500, 3430 EM Nieuwegein, <country>The Netherlands</country>. E-mail: <email>m.van.der.vorst@antoniusziekenhuis.nl</email></corresp></author-notes><pub-date pub-type="ppub"><month>08</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>29</day><month>08</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>8</month><year>2016</year></pub-date><volume>6</volume><issue>8</issue><fpage>e228</fpage><lpage/><history><date date-type="received"><day>30</day><month>06</month><year>2016</year></date><date date-type="accepted"><day>05</day><month>07</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2016 The Author(s)</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>The Author(s)</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><abstract><sec><title><text><SENT sid="1" pm="."><plain>Background: </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>As adolescents with obesity and insulin resistance may be refractory to lifestyle intervention therapy alone, additional off-label metformin therapy is often used. </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, the long-term efficacy and safety of metformin versus placebo in adolescents with obesity and insulin resistance is studied. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="4" pm="."><plain>Methods: </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>In a randomized placebo-controlled double-blinded trial, 62 adolescents with obesity aged 10–16 years old with insulin resistance received 2000 mg of metformin or placebo daily and physical training twice weekly over 18 months. </plain></SENT>
<SENT sid="6" pm="."><plain>Primary end points were change in body mass index (BMI) and insulin resistance measured by the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR). </plain></SENT>
<SENT sid="7" pm="."><plain>Secondary end points were safety and tolerability of metformin. </plain></SENT>
<SENT sid="8" pm="."><plain>Other end points were body fat percentage and HbA1c. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="9" pm="."><plain>Results: </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="10" pm="."><plain>Forty-two participants completed the 18-month study (66% girls, median age 13 (12–15) years, BMI 30.0 (28.3 to 35.0) kg m−2 and HOMA-IR 4.08 (2.40 to 5.88)). </plain></SENT>
<SENT sid="11" pm="."><plain>Median ΔBMI was +0.2 (−2.9 to 1.3) kg m−2 (metformin) versus +1.2 (−0.3 to 2.4) kg m−2 (placebo) (P=0.015). </plain></SENT>
<SENT sid="12" pm="."><plain>No significant difference was observed for HOMA-IR. </plain></SENT>
<SENT sid="13" pm="."><plain>No serious adverse events were reported. </plain></SENT>
<SENT sid="14" pm="."><plain>Median change in fat percentage was −3.1 (−4.8 to 0.3) versus −0.8 (−3.2 to 1.6)% (P=0.150), in fat mass −0.2 (−5.2 to 2.1) versus +2.0 (1.2–6.4) kg (P=0.007), in fat-free mass +2.0 (−0.1 to 4.0) versus +4.5 (1.3 to 11.6) kg (P=0.047) and in ΔHbA1c +1.0 (−1.0 to 2.3) versus +3.0 (0.0 to 5.0) mmol mol−1 (P=0.020) (metformin versus placebo). </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="15" pm="."><plain>Conclusions: </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="16" pm="."><plain>Long-term treatment with metformin in adolescents with obesity and insulin resistance results in stabilization of BMI and improved body composition compared with placebo. </plain></SENT>
<SENT sid="17" pm="."><plain>Therefore, metformin may be useful as an additional therapy in combination with lifestyle intervention in adolescents with obesity and insulin resistance. </plain></SENT>
</text></SecTag></p></sec></abstract></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="18" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="19" pm="."><plain>Childhood obesity is an important pediatric health issue, with rising prevalence rates in almost all European countries, the United States and Canada.1 While it was recently reported that the prevalence of overweight and obesity may be stabilizing, percentages are still high, that is, 37.8% and 36.6% for 11- to 15-year-old boys and girls, respectively.2 </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>Obesity increases the risk of insulin resistance (IR). </plain></SENT>
<SENT sid="21" pm="."><plain>Children with obesity with IR have a higher risk of developing type 2 diabetes mellitus,3 metabolic syndrome3, 4 and cardiovascular diseases.5, 6 Reduction of body mass index (BMI) is known to reduce the risk of developing these diseases.7, 8, 9 However, IR might be a limiting factor in losing weight in children and adolescents with obesity. </plain></SENT>
<SENT sid="22" pm="."><plain>In a study by Chiavaroli et al. the efficacy of a 1-year weight loss intervention programme in children with and without IR was evaluated. </plain></SENT>
<SENT sid="23" pm="."><plain>Children without IR achieved a reduction in BMI-s.d. score (BMI-SDS) following a weight loss intervention programme, whereas children with IR did not.10 Therefore, for children with obesity and IR additional (pharmacotherapeutic) therapies to lose weight are often considered. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>Metformin is an antidiabetic drug, which reduces peripheral insulin resistance, increases the peripheral glucose uptake and decreases gluconeogenesis of the liver.11 Although metformin is approved for the treatment of type 2 diabetes mellitus from the age of 10 years onwards, there is an increasing number of prescriptions for off-label indications such as obesity, polycystic ovarian syndrome and type 1 diabetes mellitus, with percentages reported between 8 and 20%.12, 13, 14 </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>The evidence for the efficacy of metformin in the treatment of obesity and IR in children is however scarce. </plain></SENT>
<SENT sid="26" pm="."><plain>A systematic review and meta-analysis of five randomized trials with a trial duration of 6 months (n=320) showed a moderate reduction in BMI (−1.42 kg m−2 (95% confidence interval 0.83–2.02)) and in IR measured by the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR; −2.01 (95% confidence interval 0.75–3.26)).15 Long-term data on the efficacy of metformin is limited to one trial, which studied the efficacy of metformin over 48 weeks, and reported a small reduction in BMI.16 No other studies with treatment duration more than 6 months were identified. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>Therefore, the aim of this randomized, double-blinded, placebo-controlled trial in adolescents with obesity with IR is to study the effect of metformin versus placebo on the change in BMI and in IR (measured by HOMA-IR) after 18 months. </plain></SENT>
<SENT sid="28" pm="."><plain>Secondary objectives included safety and tolerability, as well as change in body fat percentage, HbA1c, quality of life and physical fitness after 18 months. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec><title><text><SENT sid="29" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><p><text><SENT sid="30" pm="."><plain>A brief description of the methods is provided here, as the study protocol has been published elsewhere.17 </plain></SENT>
</text></p><sec><title><text><SENT sid="31" pm="."><plain>Study design and participants </plain></SENT>
</text></title><p><text><SENT sid="32" pm="."><plain>In this 18-month multicentre randomized, double-blinded, placebo-controlled trial (ClinicalTrials.gov number NCT01487993), participants were recruited at the pediatric outpatient clinics of the participating study centres (St Antonius Hospital in Nieuwegein/Utrecht (July 2011–March 2014) and Jeroen Bosch Hospital, ‘s Hertogenbosch (November 2012–March 2014), The Netherlands). </plain></SENT>
<SENT sid="33" pm="."><plain>For inclusion and exclusion criteria see Figure 1. </plain></SENT>
<SENT sid="34" pm="."><plain>All clinical measurements were performed in the pediatric outpatient clinics or day-care wards of these hospitals; the fitness tests were performed at the physical therapy outpatient clinic of the St Antonius Hospital and at the Sports Medical Centre of the Jeroen Bosch Hospital. </plain></SENT>
<SENT sid="35" pm="."><plain>The study protocol was approved by the Medical Ethical Committee of the St Antonius Hospital, Nieuwegein/Utrecht, the Netherlands, and written informed consent was obtained from the parents and if applicable, from the children (aged ⩾12 years). </plain></SENT>
<SENT sid="36" pm="."><plain>From the younger children, oral consent was obtained. </plain></SENT>
<SENT sid="37" pm="."><plain>All procedures were in accordance with the Declaration of Helsinki and the Medical Research Involving Human Subjects Act (WMO) of the Netherlands. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="38" pm="."><plain>Randomization and blinding </plain></SENT>
</text></title><p><text><SENT sid="39" pm="."><plain>Consecutive study numbers for eligible participants corresponding with the randomization code and medication number (for example, study number 1, corresponds with randomization number 1 and medication number 1) were allocated. </plain></SENT>
<SENT sid="40" pm="."><plain>The randomization schedule (in blocks of 20 per study centre) was generated by the department of Clinical Pharmacy of the St Antonius Hospital, using PASW Statistics 18.0 (SPSS Inc., Chicago, IL, USA). </plain></SENT>
<SENT sid="41" pm="."><plain>Both subjects and study staff were blinded during the 18-month treatment period. </plain></SENT>
<SENT sid="42" pm="."><plain>The randomization code was kept secured in the department of Clinical Pharmacy. </plain></SENT>
<SENT sid="43" pm="."><plain>The blind was not broken for any of the participants. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="44" pm="."><plain>Sample size </plain></SENT>
</text></title><p><text><SENT sid="45" pm="."><plain>For ΔBMI, a group sample size of 47 per group was calculated to have 90% power with a significance level of 5% to detect a difference of 2.94% in BMI (ΔBMI ±1 kg m−2). </plain></SENT>
<SENT sid="46" pm="."><plain>For ΔHOMA-IR, a group sample size of 60 participants per group was found to detect a difference of 1.6 in HOMA-IR, with a significance level of 5 and 90% power. </plain></SENT>
<SENT sid="47" pm="."><plain>Taking a dropout of 20% into account, the sample size was set at 144 participants. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48" pm="."><plain>Interventions </plain></SENT>
</text></title><sec><title><text><SENT sid="49" pm="."><plain>Medication </plain></SENT>
</text></title><p><text><SENT sid="50" pm="."><plain>All participants received either immediate-release metformin 500 mg tablets (Centrapharm, Etten-Leur, The Netherlands) or identical placebo tablets (Apotheek Haagse Ziekenhuizen, Den Haag, The Netherlands) in an increasing dosing regimen, with a maximum dose of two tablets twice daily in the fourth study week. </plain></SENT>
<SENT sid="51" pm="."><plain>Subjects were advised to take the medication during or after breakfast and dinner. </plain></SENT>
<SENT sid="52" pm="."><plain>In case of gastro-intestinal complaints, the dosage was reduced to the last well-tolerated dose. </plain></SENT>
<SENT sid="53" pm="."><plain>After symptoms had disappeared, the dosage was again increased to the maximum of two tablets twice daily, if tolerated. </plain></SENT>
<SENT sid="54" pm="."><plain>To estimate medication compliance, pill counts were performed on returned medication packages during each hospital visit (every 3 months). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="55" pm="."><plain>Physical training </plain></SENT>
</text></title><p><text><SENT sid="56" pm="."><plain>Physical training by a physical therapist was offered twice weekly to all participants. </plain></SENT>
<SENT sid="57" pm="."><plain>During the monthly phone calls and three monthly visits participants were encouraged to attend these trainings. </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="58" pm="."><plain>Outcomes </plain></SENT>
</text></title><sec><title><text><SENT sid="59" pm="."><plain>Primary outcome measures </plain></SENT>
</text></title><p><text><SENT sid="60" pm="."><plain>Primary end point was the change in BMI after 18 months (ΔBMI). </plain></SENT>
<SENT sid="61" pm="."><plain>BMI was calculated as weight (kg)/((height (m))2, and was assessed every 3 months. </plain></SENT>
<SENT sid="62" pm="."><plain>The corresponding age- and sex-adjusted BMI, the BMI-SDS, was calculated by the ‘TNO Groeicalculator voor professionals' (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://groeiweb.pgdata.nl/calculator.asp">https://groeiweb.pgdata.nl/calculator.asp</ext-link>). </plain></SENT>
<SENT sid="63" pm="."><plain>As second primary outcome, ΔHOMA-IR over 18 months (HOMA-IR=fasting plasma glucose(mmol l−1) × fasting plasma insulin(mU l−1)/22.5) was evaluated.18 Fasting plasma glucose and fasting plasma insulin were measured and HOMA-IR was calculated every 3 months. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="64" pm="."><plain>Secondary outcome measures </plain></SENT>
</text></title><p><text><SENT sid="65" pm="."><plain>Secondary end points were safety and tolerability of metformin. </plain></SENT>
<SENT sid="66" pm="."><plain>Safety outcome measures were renal and hepatic function tests, measured at baseline and every 3 months during treatment. </plain></SENT>
<SENT sid="67" pm="."><plain>Vitamin B12 levels were measured, and levels &lt;140 pmol l−1 were defined as abnormal. </plain></SENT>
<SENT sid="68" pm="."><plain>Tolerability was assessed by the amount of observed adverse events, and by the achieved maximum dosage levels. </plain></SENT>
<SENT sid="69" pm="."><plain>The reasons for dropout of participants were registered. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="70" pm="."><plain>Other outcome measures </plain></SENT>
</text></title><p><text><SENT sid="71" pm="."><plain>Other end points were change in body fat percentage measured by bio-impedance analysis using a leg-to-leg bio-impedance analysis measurement, and HbA1c after 18 months. </plain></SENT>
<SENT sid="72" pm="."><plain>Furthermore, change in quality of life assessed using a validated Dutch translation of the Impact of Weight on Quality of Life-Kids (IWQOL-kids) questionnaire,19, 20 and change in physical fitness assessed during validated fitness tests after 18 months were analysed. </plain></SENT>
<SENT sid="73" pm="."><plain>Participants were asked to fulfil a dietary diary at baseline, 9 months and 18 months to calculate caloric intake. </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="74" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="75" pm="."><plain>All participants who started treatment (that is, they used at least one tablet of metformin or placebo) and finished follow-up of 18 months were analysed. </plain></SENT>
<SENT sid="76" pm="."><plain>As most parameters were not normally distributed, data are reported as medians with interquartile ranges. </plain></SENT>
<SENT sid="77" pm="."><plain>To assess the effect of metformin versus placebo after 18 months of treatment on the continuous scales, the Mann–Whitney U-test was applied. </plain></SENT>
<SENT sid="78" pm="."><plain>To compare the frequencies of categorical, dichotomous data, a χ2-test was used. </plain></SENT>
<SENT sid="79" pm="."><plain>All analyses have been conducted with SPSS for Windows version 22.0 (IBM Corp., Armonk, NY, USA). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec><title><text><SENT sid="80" pm="."><plain>Results </plain></SENT>
</text></title><sec><title><text><SENT sid="81" pm="."><plain>Participants </plain></SENT>
</text></title><p><text><SENT sid="82" pm="."><plain>In all, 127 participants were assessed for eligibility (Figure 1). </plain></SENT>
<SENT sid="83" pm="."><plain>A total of 62 participants were allocated to metformin (n=32) or placebo (n=30), of which 42 could be included in the final analysis (Figure 1). </plain></SENT>
<SENT sid="84" pm="."><plain>One patient in the placebo group was excluded from the analysis, because this patient was an outlier with a change in BMI-SDS of −4.47. </plain></SENT>
<SENT sid="85" pm="."><plain>There was no difference in baseline age, sex, BMI, HbA1c and HOMA-IR between the participants lost to follow-up and participants who completed the 18-month treatment period (Supplementary Tables 1 and 2). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="86" pm="."><plain>Baseline characteristics </plain></SENT>
</text></title><p><text><SENT sid="87" pm="."><plain>Baseline characteristics of the analysed participants are presented in Table 1. </plain></SENT>
<SENT sid="88" pm="."><plain>Overall, more girls than boys were included. </plain></SENT>
<SENT sid="89" pm="."><plain>In both groups, most participants were early pubertal and family history positive for obesity and diabetes mellitus was frequently reported. </plain></SENT>
<SENT sid="90" pm="."><plain>Median BMI at baseline was 29.8 (28.1–34.5) kg m−2 for the metformin and 30.5 (28.7–38.6) kg m−2 for the placebo groups, corresponding with an age- and sex-specific BMI-SDS of 3.10 (2.72–3.52) and 3.38 (3.10–4.20), respectively (Table 1). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="91" pm="."><plain>Medication compliance </plain></SENT>
</text></title><p><text><SENT sid="92" pm="."><plain>Two participants did not return any medication packages during the study. </plain></SENT>
<SENT sid="93" pm="."><plain>In the metformin group 74% (17/22 participants) returned their medication boxes at least 4 times, versus 69% in the placebo group (13/18 participants). </plain></SENT>
<SENT sid="94" pm="."><plain>The returned boxes contained on average 28% and 24% of its content for the metformin and placebo groups, respectively. </plain></SENT>
<SENT sid="95" pm="."><plain>In case of full compliance, the remaining content should be 7% because all medication boxes had a surplus when dispensed. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="96" pm="."><plain>Effect on BMI and HOMA-IR </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>Table 2 presents the 18-month treatment results of metformin versus placebo; the absolute values for BMI and other parameters, as well as changes over 0–18 months are displayed. </plain></SENT>
<SENT sid="98" pm="."><plain>After 18 months, median ΔBMI was +0.2 (−2.9 to 1.3) kg m−2 in the metformin group versus +1.2 (−0.3 to 2.4) kg m−2 in the placebo group (P=0.015). Figure 2 shows that this difference between the two groups can be explained by a decrease in ΔBMI in the metformin group during the first 6–9 months of treatment and subsequent return to baseline values, which was not observed in the placebo group. </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>No significant difference was observed for ΔHOMA-IR after 18 months between both groups (Table 2). Figure 2 shows that in accordance with this lack of difference between the groups at 18 months, there is also no evidence for a difference in profile of ΔHOMA-IR over time during the study. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="100" pm="."><plain>Secondary end points safety and tolerability </plain></SENT>
</text></title><sec><title><text><SENT sid="101" pm="."><plain>Safety </plain></SENT>
</text></title><p><text><SENT sid="102" pm="."><plain>No severe adverse advents occurred in either group. </plain></SENT>
<SENT sid="103" pm="."><plain>There were no derangements of renal or hepatic function (Table 3). </plain></SENT>
<SENT sid="104" pm="."><plain>In three participants of the metformin group, vitamin B12 levels below the threshold of 140 pmol l−1 were measured at 18 months (136, 117 and 108 pmol l−1, respectively). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="105" pm="."><plain>Tolerability </plain></SENT>
</text></title><p><text><SENT sid="106" pm="."><plain>Two out of nine participants lost to follow-up in the metformin group discontinued treatment because of adverse events. </plain></SENT>
<SENT sid="107" pm="."><plain>One patient had severe nausea despite dosage reductions. </plain></SENT>
<SENT sid="108" pm="."><plain>The other patient suffering from abdominal pain and discomfort, was not willing to try dosage reductions and terminated study participation. </plain></SENT>
<SENT sid="109" pm="."><plain>Four participants in the metformin group did not tolerate the maximum dose of 2000 mg daily because of adverse events; these participants used 1000 (n=3) or 1500 mg daily (n=1). </plain></SENT>
<SENT sid="110" pm="."><plain>In the placebo group, no participants dropped out because of adverse events. </plain></SENT>
</text></p><p><text><SENT sid="111" pm="."><plain>Well-known side effects of metformin, nausea and diarrhoea, were reported in both groups during the study, but participants using metformin suffered significantly more from nausea (73.9%, n=17) than the participants receiving placebo (42.1%, n=8; P=0.037). </plain></SENT>
<SENT sid="112" pm="."><plain>Diarrhoea occurred in 60.9% (n=14) of the metformin users and 47.4% (n=9) of the placebo users (P=0.38; Table 3). </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="113" pm="."><plain>Effect of metformin on HbA1c and body composition </plain></SENT>
</text></title><p><text><SENT sid="114" pm="."><plain>Table 2 and Figure 3 show that HbA1c increased in both groups, with a significantly larger increase in the placebo group (P=0.02). </plain></SENT>
<SENT sid="115" pm="."><plain>None of the participants had HbA1c values above the normal threshold after 18 months. </plain></SENT>
</text></p><p><text><SENT sid="116" pm="."><plain>In the metformin group, fat mass decreased versus an increase in the placebo group (P=0.007) (Table 2; Figure 3). </plain></SENT>
<SENT sid="117" pm="."><plain>Concerning fat-free mass, in the metformin group the increase was+2.0 (−0.1 to 4.0) versus+4.5 (1.3 to 11.6) kg in the placebo group (P=0.047). </plain></SENT>
<SENT sid="118" pm="."><plain>There was no significant change in body fat percentage (Figure 3). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="119" pm="."><plain>Effect of metformin on quality of life and physical fitness </plain></SENT>
</text></title><p><text><SENT sid="120" pm="."><plain>Table 2 shows results for quality of life measured by IWQOL-kids. </plain></SENT>
<SENT sid="121" pm="."><plain>For all sections and the total score, there was no difference in quality of life. </plain></SENT>
<SENT sid="122" pm="."><plain>Owing to a poor attendance at the physical tests after 18 months, physical fitness tests could only be analysed in a small subgroup (metformin n=15, placebo n=7; Table 2). </plain></SENT>
<SENT sid="123" pm="."><plain>At baseline, more than 50% of the participants completed the shuttle walk test, therefore the median score of the shuttle walk test was similar to the maximum score, and no significant differences were observed in this small subgroup. </plain></SENT>
<SENT sid="124" pm="."><plain>Dietary diaries were not completed and returned adequately, and therefore the caloric intake could not be calculated and analysed. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="125" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="126" pm="."><plain>In this randomized, double-blinded, placebo-controlled trial in adolescents with obesity and insulin resistance, we found that assignment to the metformin group was associated with an initial decrease in BMI over the first 6–9 months of treatment after which BMI returned to baseline level, whereas BMI increased in placebo users. </plain></SENT>
<SENT sid="127" pm="."><plain>Changes in body composition and HbA1c over 18 months were also in favour of metformin. </plain></SENT>
<SENT sid="128" pm="."><plain>In contrast, in the placebo group, a steady increase in BMI was observed over 18 months. </plain></SENT>
<SENT sid="129" pm="."><plain>No serious adverse events were reported and most participants tolerated metformin up to 1000 mg twice daily; only two participants discontinued treatment because of adverse events. </plain></SENT>
</text></p><p><text><SENT sid="130" pm="."><plain>Our study is the first study in an obese non-diabetic pediatric population reporting on the long-term effect (&gt;1 year of treatment) of metformin on BMI. </plain></SENT>
<SENT sid="131" pm="."><plain>Beneficial effects on BMI upon short-term treatment with metformin have been reported before by Burgert et al.,21 who reported upon 4-month treatment a reduction in BMI of −0.9 kg m−2 (95% confidence interval −2.0 to 0.3 kg m−2) versus an increase in BMI of +1.2 kg m−2 (−0.1 to 2.4 kg m−2) in placebo. </plain></SENT>
<SENT sid="132" pm="."><plain>Upon 48 weeks of treatment, Wilson et al.16 reported a significant reduction in BMI of −0.9±0.5 kg m−2 for the metformin group versus +0.2±0.5 kg m−2 in the placebo group (P=0.03). </plain></SENT>
<SENT sid="133" pm="."><plain>Comparing our results with these previous short-term results, it seems that our results after 12 months closely resemble them (that is median ΔBMI −1.0 (−3.4 to 0.6) kg m−2 for metformin versus +0.6 (−0.2 to 2.1) kg m−2 for placebo, Figure 2)). </plain></SENT>
<SENT sid="134" pm="."><plain>In our study, where we report on treatment effects after 18 months, the difference between metformin and placebo remained significant even though it seems that BMI values return to baseline in the metformin group. </plain></SENT>
<SENT sid="135" pm="."><plain>However, in the placebo group there was no evidence of a decrease in BMI (Figure 2). </plain></SENT>
<SENT sid="136" pm="."><plain>An intriguing question is therefore how BMI will change over time after these 18 months. </plain></SENT>
<SENT sid="137" pm="."><plain>Lavine et al. treated children with obesity and non-alcoholic fatty liver disease for 96 weeks with metformin.22 However, the treatment in this study was not primarily focused on weight loss, and participants did not receive lifestyle intervention. </plain></SENT>
<SENT sid="138" pm="."><plain>They reported changes in BMI after 96 weeks of +1.3 (0.6–2.0) kg m−2 for metformin versus +1.9 (1.1–2.7) kg m−2 for placebo (P=0.25).22 This finding illustrates that metformin without lifestyle intervention may not be effective in changing BMI. </plain></SENT>
<SENT sid="139" pm="."><plain>As a consequence, follow-up results of our study (open-label results) upon 36 months' treatment with metformin with lifestyle intervention will need to be awaited.17 Until then, in our opinion, lifestyle intervention remains an important part of obesity treatment to which metformin therapy over 18 months seems to be of added value to reduce BMI. </plain></SENT>
</text></p><p><text><SENT sid="140" pm="."><plain>In our study, two participants discontinued treatment and four participants received a reduced dosage because of adverse events, even though there were no serious adverse events or derangements in hepatic and renal function tests. </plain></SENT>
<SENT sid="141" pm="."><plain>These findings are comparable to the study of Wilson et al.16 of 48 weeks, where one patient dropped out because of nausea. </plain></SENT>
<SENT sid="142" pm="."><plain>In studies where metformin was administered over 2–6 months, no severe adverse events, elevated hepatic or renal function tests, or decreased vitamin B12 were reported. </plain></SENT>
<SENT sid="143" pm="."><plain>Concerning vitamin B12, in our study, three participants in the metformin group had decreased vitamin B12 levels and therefore monitoring of vitamin B12 levels upon long-term use of metformin should be considered. </plain></SENT>
<SENT sid="144" pm="."><plain>In all studies nausea and diarrhoea were the most frequently reported side effects.21, 23, 24, 25, 26, 27, 28, 29 Even though these side effects of metformin are mostly mild and self-limiting, a small number of participants (6%) did not tolerate metformin because of these side effects.28 It is known that the incidence of gastro-intestinal side effects is higher in patients using immediate-release metformin compared with extended-release metformin.30, 31, 32 Therefore, the use of extended-release metformin could be considered in the small number of patients with serious gastro-intestinal side effects. </plain></SENT>
<SENT sid="145" pm="."><plain>From this study, it seems that safety and tolerability of long-term metformin treatment is comparable to short-term treatment (6 months to 48 weeks), with no serious adverse events and only a small percentage of participants who do not tolerate metformin. </plain></SENT>
</text></p><p><text><SENT sid="146" pm="."><plain>In the current study, participants treated with metformin were found to have an improved body composition measured by bio-impedance analysis after 18 months, with a decrease in fat mass and increase in fat-free mass compared with placebo. </plain></SENT>
<SENT sid="147" pm="."><plain>In the placebo group, the change in fat-free mass was larger than the change in fat mass. </plain></SENT>
<SENT sid="148" pm="."><plain>The placebo group has a larger increase in height (Table 2) during the 18 months; the increase in fat-free mass might be related to this increase in height. </plain></SENT>
<SENT sid="149" pm="."><plain>We assume that this increase in height, and therewith in fat-free mass, is caused by a difference in pubertal stage during the study. </plain></SENT>
<SENT sid="150" pm="."><plain>At t=18months, in the metformin group 38.1% was pubertal (Tanner stage 2–4) and 57.1% postpubertal (Tanner stage 5), compared with 64.7% pubertal and 35.3% postpubertal in the placebo group. </plain></SENT>
<SENT sid="151" pm="."><plain>In the metformin group an increase in fat-free mass in accordance with their increase in height over 18 months was found, without an increase in fat mass, resulting in a stable BMI. </plain></SENT>
<SENT sid="152" pm="."><plain>Also in other studies, a favourable effect of metformin on body composition (measured by dual-energy X-ray absorptiometry or bio-impedance analysis) after 2–11 months of treatment, compared with placebo was reported.16, 21, 24, 29 In adults, a decrease in body fat percentage was related to a decrease in systolic and diastolic blood pressure and cholesterol levels.33 Therefore, a change in body composition during metformin treatment might have a positive influence on cardiovascular risk factors. </plain></SENT>
</text></p><p><text><SENT sid="153" pm="."><plain>A limitation of our study is the number of included participants. </plain></SENT>
<SENT sid="154" pm="."><plain>For the primary end point (ΔBMI), 66% of the targeted number of participants was included, while for the change in HOMA-IR this percentage was only 43%, despite a prolongation of the inclusion period by 1.5 years. </plain></SENT>
<SENT sid="155" pm="."><plain>Furthermore, the dropout rate was 32%, whereas a dropout rate of 20% was anticipated. </plain></SENT>
<SENT sid="156" pm="."><plain>This high dropout rate illustrates the difficulties in motivating adolescents with obesity for long-term treatment and follow-up. </plain></SENT>
<SENT sid="157" pm="."><plain>This difficulty is underlined by the poor attendance at physical fitness tests and by the dietary diaries, which had limited completeness and reliability. </plain></SENT>
<SENT sid="158" pm="."><plain>Frequent phone calls and written reminders by the study staff did not improve the compliance. </plain></SENT>
<SENT sid="159" pm="."><plain>The low number of included participants and high dropout rate could have resulted in insufficient power to statistically test our hypotheses. </plain></SENT>
<SENT sid="160" pm="."><plain>However, although our study has less power than anticipated, we were able to detect a significant effect of metformin on the primary outcome measure (ΔBMI). </plain></SENT>
<SENT sid="161" pm="."><plain>For comparison, with respect to the IR outcome, other studies with sufficient power did not find an effect on IR after 6 months and 48 weeks either.16, 25, 28 Another limitation is the measurement of IR. </plain></SENT>
<SENT sid="162" pm="."><plain>All participants had HOMA-IR ⩾3.4 during the screening for eligibility. </plain></SENT>
<SENT sid="163" pm="."><plain>At baseline, which was planned within a few weeks from screening, some participants had HOMA-IR values &lt;3.4, while still being obese (BMI-SDS &gt;2.3). </plain></SENT>
<SENT sid="164" pm="."><plain>As a possible explanation for this finding, participants may not tell the truth about their fasting state during the screening. </plain></SENT>
<SENT sid="165" pm="."><plain>Another reason may be the large coefficient of variation that has been reported for fasting insulin.34, 35 As HOMA-IR is based on fasting insulin, HOMA-IR will vary as well resulting in HOMA-IR&lt;3.4, thereby explaining the lack of difference in this parameter. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec><title><text><SENT sid="166" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="167" pm="."><plain>In conclusion, long-term treatment with metformin in adolescents with obesity and insulin resistance results in a stabilization of BMI and improved body composition compared with placebo. </plain></SENT>
<SENT sid="168" pm="."><plain>Therefore, metformin may be considered a safe additional therapy in combination with lifestyle intervention. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="AUTH_CONT"><ack><p>We acknowledge ZonMw for funding our study and all members of the project group responsible for submitting the project idea to the ZonMw Program for Priority Medicines for Children. Rifka Peeters of the Department of Clinical Pharmacy of the St Antonius Hospital is acknowledged for supporting the logistics of trial medication, and research nurses Bianca Broere and Kitty Blauwendraat for their assistance in the data collection. The study was funded by a grant of the ZonMw Program of Priority Medicines for Children</p><p><bold>Author contributions</bold></p><p>MPA collected the data, carried out the data analyses, drafted the initial manuscript and approved the final manuscript as submitted; MAJE collected the data, critically reviewed the manuscript and approved the final manuscript as submitted; EMWG supervised the data analysis, critically reviewed the manuscript and approved the final manuscript as submitted; EGAHM conceptualized and designed the study, critically reviewed the manuscript and approved the final manuscript as submitted; MMJV and CAJK conceptualized and designed the study, drafted the initial manuscript and approved the final manuscript as submitted.</p></ack></SecTag><fn-group><fn><p><text><SENT sid="169" pm="."><plain>Supplementary Information accompanies this paper on the Nutrition &amp; Diabetes website (http://www.nature.com/nutd) </plain></SENT>
</text></p></fn></fn-group><SecTag type="SUPPL"><notes><p>The authors declare no conflict of interest.</p></notes></SecTag><SecTag type="REF"><ref-list><ref id="bib1"><text><SENT sid="170" pm="."><plain>Ahluwalia N, Dalmasso P, Rasmussen M, Lipsky L, Currie C, Haug E et al. Trends in overweight prevalence among 11-, 13- and 15-year-olds in 25 countries in Europe, Canada and USA from 2002 to 2010. Eur J Public Health 2015; 25(Suppl 2): 28–32. </plain></SENT>
</text></ref><ref id="bib2"><text><SENT sid="171" pm="."><plain>van Jaarsveld CH, Gulliford MC. Childhood obesity trends from primary care electronic health records in England between 1994 and 2013: population-based cohort study. Arch Dis Child 2015; 100: 214–219.25633067 </plain></SENT>
</text></ref><ref id="bib3"><text><SENT sid="172" pm="."><plain>Levy-Marchal C, Arslanian S, Cutfield W, Sinaiko A, Druet C, Marcovecchio ML et al. Insulin resistance in children: consensus, perspective, and future directions. J Clin Endocrinol Metab 2010; 95: 5189–5198.20829185 </plain></SENT>
</text></ref><ref id="bib4"><text><SENT sid="173" pm="."><plain>Burrows RA, Leiva LB, Weisstaub G, Lera LM, Albala CB, Blanco E et al. High HOMA-IR, adjusted for puberty, relates to the metabolic syndrome in overweight and obese Chilean youths. Pediatr Diabetes 2011; 12(3 Pt 2): 212–218.21426454 </plain></SENT>
</text></ref><ref id="bib5"><text><SENT sid="174" pm="."><plain>Pankow JS, Jacobs Jr DR, Steinberger J, Moran A, Sinaiko AR. Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome. Diabetes Care 2004; 27: 775–780.14988301 </plain></SENT>
</text></ref><ref id="bib6"><text><SENT sid="175" pm="."><plain>Cruz ML, Shaibi GQ, Weigensberg MJ, Spruijt-Metz D, Ball GD, Goran MI. Pediatric obesity and insulin resistance: chronic disease risk and implications for treatment and prevention beyond body weight modification. Annu Rev Nutr 2005; 25: 435–468.16011474 </plain></SENT>
</text></ref><ref id="bib7"><text><SENT sid="176" pm="."><plain>Oberbach A, Neuhaus J, Inge T, Kirsch K, Schlichting N, Bluher S et al. Bariatric surgery in severely obese adolescents improves major comorbidities including hyperuricemia. Metabolism 2014; 63: 242–249.24332707 </plain></SENT>
</text></ref><ref id="bib8"><text><SENT sid="177" pm="."><plain>Arrigo T, Gitto E, Ferrau V, Munafo C, Alibrandi A, Marseglia GL et al. Effect of weight reduction on leptin, total ghrelin and obestatin concentrations in prepubertal children. J Biol Regul Homeost Agents 2012; 26(1 Suppl): S95–S103.22691243 </plain></SENT>
</text></ref><ref id="bib9"><text><SENT sid="178" pm="."><plain>Gronbaek H, Lange A, Birkebaek NH, Holland-Fischer P, Solvig J, Horlyck A et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr 2012; 54: 223–228.21760546 </plain></SENT>
</text></ref><ref id="bib10"><text><SENT sid="179" pm="."><plain>Chiavaroli V, Giannini C, D'Adamo E, de Giorgis T, Torello M, D'Orazio N et al. Weight loss in obese prepubertal children: the influence of insulin resistance. Endocr Res 2013; 38: 48–57.22913806 </plain></SENT>
</text></ref><ref id="bib11"><text><SENT sid="180" pm="."><plain>Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059–4067.8923861 </plain></SENT>
</text></ref><ref id="bib12"><text><SENT sid="181" pm="."><plain>Fazeli Farsani S, Souverein PC, Overbeek JA, van der Vorst MM, Knibbe CA, Herings RM et al. Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands. Br J Clin Pharmacol 2015; 80: 294–303.25683632 </plain></SENT>
</text></ref><ref id="bib13"><text><SENT sid="182" pm="."><plain>Hsia Y, Dawoud D, Sutcliffe AG, Viner RM, Kinra S, Wong IC. Unlicensed use of metformin in children and adolescents in the UK. Br J Clin Pharmacol 2012; 73: 135–139.21762204 </plain></SENT>
</text></ref><ref id="bib14"><text><SENT sid="183" pm="."><plain>Kostev K, Richter H. Unlicensed use of metformin in children and adolescents in Germany and France. Br J Clin Pharmacol 2012; 73: 307–308.22023105 </plain></SENT>
</text></ref><ref id="bib15"><text><SENT sid="184" pm="."><plain>Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009; 32: 1743–1745.19502540 </plain></SENT>
</text></ref><ref id="bib16"><text><SENT sid="185" pm="."><plain>Wilson DM, Abrams SH, Aye T, Lee PD, Lenders C, Lustig RH et al. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med 2010; 164: 116–123.20124139 </plain></SENT>
</text></ref><ref id="bib17"><text><SENT sid="186" pm="."><plain>van der Aa MP, Elst MA, van Mil EG, Knibbe CA, van der Vorst MM. METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study. Trials 2014; 15: 207.24899137 </plain></SENT>
</text></ref><ref id="bib18"><text><SENT sid="187" pm="."><plain>Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.3899825 </plain></SENT>
</text></ref><ref id="bib19"><text><SENT sid="188" pm="."><plain>Kolotkin RL, Zeller M, Modi AC, Samsa GP, Quinlan NP, Yanovski JA et al. Assessing weight-related quality of life in adolescents. Obesity (Silver Spring) 2006; 14: 448–457.16648616 </plain></SENT>
</text></ref><ref id="bib20"><text><SENT sid="189" pm="."><plain>Wouters EJM, Geenen R, Kolotkin RL, Vingerhoets AJJM. Met lichaamsgewicht samenhangende kwaliteit van leven bij adolescenten. </plain></SENT>
<SENT sid="190" pm="."><plain>Psychometrische kwaliteit van de Nederlandse vertaling van de IWQOL-Kids. Tijdschr Kindergeneeskd 2010; 78: 119–125. </plain></SENT>
</text></ref><ref id="bib21"><text><SENT sid="191" pm="."><plain>Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes 2008; 9: 567–576.18761646 </plain></SENT>
</text></ref><ref id="bib22"><text><SENT sid="192" pm="."><plain>Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659–1668.21521847 </plain></SENT>
</text></ref><ref id="bib23"><text><SENT sid="193" pm="."><plain>Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: E55.11335776 </plain></SENT>
</text></ref><ref id="bib24"><text><SENT sid="194" pm="."><plain>Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50: 1457–1461.11735093 </plain></SENT>
</text></ref><ref id="bib25"><text><SENT sid="195" pm="."><plain>Kendall D, Vail A, Amin R, Barrett T, Dimitri P, Ivison F et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab 2013; 98: 322–329.23175691 </plain></SENT>
</text></ref><ref id="bib26"><text><SENT sid="196" pm="."><plain>Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008; 152: 817–822.18492523 </plain></SENT>
</text></ref><ref id="bib27"><text><SENT sid="197" pm="."><plain>Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006; 91: 2074–2080.16595599 </plain></SENT>
</text></ref><ref id="bib28"><text><SENT sid="198" pm="."><plain>Wiegand S, l'Allemand D, Hubel H, Krude H, Burmann M, Martus P et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol 2010; 163: 585–592.20639355 </plain></SENT>
</text></ref><ref id="bib29"><text><SENT sid="199" pm="."><plain>Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 2011; 60: 477–485.21228310 </plain></SENT>
</text></ref><ref id="bib30"><text><SENT sid="200" pm="."><plain>Ali S, Fonseca V. Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother 2012; 13: 1797–1805.22775758 </plain></SENT>
</text></ref><ref id="bib31"><text><SENT sid="201" pm="."><plain>Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004; 20: 565–572.15119994 </plain></SENT>
</text></ref><ref id="bib32"><text><SENT sid="202" pm="."><plain>Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29: 759–764.16567811 </plain></SENT>
</text></ref><ref id="bib33"><text><SENT sid="203" pm="."><plain>Diaz Cisneros FJ, Rivera Cisneros AE, Lopez Martinez MG, Garcia Gonzalez MR, Lopez Ortega H. Effects of an aerobic exercise program and diet on body composition and cardiovascular function in obese persons. Arch Inst Cardiol Mex 1986; 56: 527–533.2952080 </plain></SENT>
</text></ref><ref id="bib34"><text><SENT sid="204" pm="."><plain>Antuna-Puente B, Faraj M, Karelis AD, Garrel D, Prud'homme D, Rabasa-Lhoret R et al. HOMA or QUICKI: Is it useful to test the reproducibility of formulas? Diabetes Metab 2008; 34: 294–296.18468934 </plain></SENT>
</text></ref><ref id="bib35"><text><SENT sid="205" pm="."><plain>Henriquez S, Jara N, Bunout D, Hirsch S, de la Maza MP, Leiva L et al. Variability of formulas to assess insulin sensitivity and their association with the Matsuda index. Nutr Hosp 2013; 28: 1594–1598.24160221 </plain></SENT>
</text></ref></ref-list></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Table 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nutd201637x1.doc"><caption><p><text><SENT sid="206" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob2"><label>Supplementary Table 2</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nutd201637x2.doc"><caption><p><text><SENT sid="207" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1"><label>Figure 1</label><caption><p><text><SENT sid="208" pm="."><plain>Consort flow diagram. </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nutd201637f1"/></fig></SecTag><SecTag type="FIG"><fig id="fig2"><label>Figure 2</label><caption><p><text><SENT sid="209" pm="."><plain>Effect of metformin on primary end points BMI and HOMA-IR after 18 months. </plain></SENT>
<SENT sid="210" pm="."><plain>(a) Change in BMI and HOMA-IR between t=0 and 18 months; (b) median ΔBMI and ΔHOMA-IR over time; (c) median BMI and HOMA-IR over time. </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nutd201637f2"/></fig></SecTag><SecTag type="FIG"><fig id="fig3"><label>Figure 3</label><caption><p><text><SENT sid="211" pm="."><plain>Effect of metformin on HbA1c and body composition after 18 months. </plain></SENT>
<SENT sid="212" pm="."><plain>Boxplots represent the Δ values between t=0 and 18 months. </plain></SENT>
<SENT sid="213" pm="."><plain>Graphs represent median values. </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nutd201637f3"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tbl1"><label>Table 1</label><caption><title>Baseline characteristics of the analysed participants</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><text><SENT sid="214" pm="."><plain>  </plain></SENT>
</text></th><th align="center" valign="top" char="(" charoff="50"><text><SENT sid="215" pm="."><plain>Metformin (n=23) </plain></SENT>
</text></th><th align="center" valign="top" char="(" charoff="50"><text><SENT sid="216" pm="."><plain>Placebo (n=19) </plain></SENT>
</text></th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" charoff="50"><text><SENT sid="217" pm="."><plain>Clinical measurements </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="218" pm="."><plain> Age (years) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="219" pm="."><plain>13.6 (12.6 to 15.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="220" pm="."><plain>12.0 (11.3 to 14.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="221" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="222" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="223" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><text><SENT sid="224" pm="."><plain>Gender, n (%) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="225" pm="."><plain> Boys </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="226" pm="."><plain>6 (26.1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="227" pm="."><plain>8 (42.1) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="228" pm="."><plain> Girls </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="229" pm="."><plain>17 (73.9) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="230" pm="."><plain>11 (57.9) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="231" pm="."><plain> Height (cm) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="232" pm="."><plain>162.9 (159.0 to 168.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="233" pm="."><plain>162.0 (160.0 to 166.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="234" pm="."><plain> Height-SDS </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="235" pm="."><plain>−0.08 (−0.65 to 0.71) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="236" pm="."><plain>0.51 (−0.15 to 1.34) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="237" pm="."><plain> Weight (kg) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="238" pm="."><plain>82.2 (75.4 to 92.7) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="239" pm="."><plain>86.1 (74.0 to 103.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="240" pm="."><plain> BMI (kg m−2) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="241" pm="."><plain>29.8 (28.1 to 34.5) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="242" pm="."><plain>30.5 (28.7 to 38.6) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="243" pm="."><plain> BMI-SDS </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="244" pm="."><plain>3.10 (2.72 to 3.52) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="245" pm="."><plain>3.38 (3.10 to 4.20) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="246" pm="."><plain> Hip circumference (cm) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="247" pm="."><plain>101.0 (93.0 to 107.8) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="248" pm="."><plain>100.8 (96.9 to 112.3)a </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="249" pm="."><plain> Waist circumference (cm) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="250" pm="."><plain>97.0 (94.0 to 106.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="251" pm="."><plain>103.8 (100.0 to 119.4)a </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="252" pm="."><plain> Waist-to-hip ratio </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="253" pm="."><plain>1.00 (0.95 to 1.04) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="254" pm="."><plain>1.05 (0.96 to 1.10)a </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="255" pm="."><plain> Systolic blood pressure (mm Hg) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="256" pm="."><plain>118 (115 to 124) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="257" pm="."><plain>119 (113 to 126) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="258" pm="."><plain> Diastolic blood pressure (mm Hg) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="259" pm="."><plain>69 (61 to 72) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="260" pm="."><plain>67 (57 to 77) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="261" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="262" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="263" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><text><SENT sid="264" pm="."><plain>Tanner stage, n (%) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="265" pm="."><plain> Prepubertal (Tanner stage 1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="266" pm="."><plain>3 (13.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="267" pm="."><plain>3 (16.7) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="268" pm="."><plain> Pubertal (Tanner stage 2–4) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="269" pm="."><plain>17 (74.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="270" pm="."><plain>12 (66.6) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="271" pm="."><plain> Postpubertal (Tanner stage 5) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="272" pm="."><plain>3 (13.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="273" pm="."><plain>3 (16.7) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="274" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="275" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="276" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><text><SENT sid="277" pm="."><plain>Family history, first and/or second degree, n (%) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="278" pm="."><plain> Obesity </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="279" pm="."><plain>20 (86.9) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="280" pm="."><plain>16 (84.2) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="281" pm="."><plain> Diabetes mellitus </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="282" pm="."><plain>15 (65.2) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="283" pm="."><plain>9 (47.4) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="284" pm="."><plain> Hypercholesterolemia </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="285" pm="."><plain>14 (60.9) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="286" pm="."><plain>9 (47.4) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="287" pm="."><plain> Hypertension </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="288" pm="."><plain>16 (69.5) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="289" pm="."><plain>13 (68.4) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="290" pm="."><plain> Cardiovascular disease </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="291" pm="."><plain>14 (60.9) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="292" pm="."><plain>14 (73.7) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="293" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="294" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="295" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><text><SENT sid="296" pm="."><plain>Highest level of education, n (%) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="297" pm="."><plain> Participant </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="298" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="299" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="300" pm="."><plain>  Lowest </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="301" pm="."><plain>4 (17.4) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="302" pm="."><plain>8 (42.1) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="303" pm="."><plain>  Low </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="304" pm="."><plain>16 (69.6) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="305" pm="."><plain>7 (36.8) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="306" pm="."><plain>  Middle </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="307" pm="."><plain>3 (13.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="308" pm="."><plain>4 (21.1) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="309" pm="."><plain>  High </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="310" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="311" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="312" pm="."><plain> Father </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="313" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="314" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="315" pm="."><plain>  Lowest </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="316" pm="."><plain>2 (8.7) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="317" pm="."><plain>1 (5.3) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="318" pm="."><plain>  Low </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="319" pm="."><plain>9 (39.1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="320" pm="."><plain>5 (26.3) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="321" pm="."><plain>  Middle </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="322" pm="."><plain>7 (30.4) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="323" pm="."><plain>9 (47.4) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="324" pm="."><plain>  High </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="325" pm="."><plain>3 (13.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="326" pm="."><plain>2 (10.5) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="327" pm="."><plain>  Unknown </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="328" pm="."><plain>2 (8.7) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="329" pm="."><plain>2 (10.5) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="330" pm="."><plain> Mother </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="331" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="332" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="333" pm="."><plain>  Lowest </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="334" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="335" pm="."><plain>3 (15.8) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="336" pm="."><plain>  Low </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="337" pm="."><plain>10 (43.5) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="338" pm="."><plain>10 (52.6) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="339" pm="."><plain>  Middle </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="340" pm="."><plain>8 (34.8) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="341" pm="."><plain>4 (21.1) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="342" pm="."><plain>  High </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="343" pm="."><plain>4 (17.4) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="344" pm="."><plain>0 (0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="345" pm="."><plain>  Unknown </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="346" pm="."><plain>1 (4.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="347" pm="."><plain>2 (10.5) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="348" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="349" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="350" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><text><SENT sid="351" pm="."><plain>Biochemical measurements </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="352" pm="."><plain> Glucose 0′ (mmol l−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="353" pm="."><plain>4.8 (4.7 to 5.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="354" pm="."><plain>4.8 (4.5 to 5.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="355" pm="."><plain> Glucose 120′ (mmol l−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="356" pm="."><plain>6.0 (5.6 to 6.6) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="357" pm="."><plain>5.9 (4.8 to 7.2) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="358" pm="."><plain> Insulin 0′ (mU l) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="359" pm="."><plain>18.0 (11.0 to 27.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="360" pm="."><plain>23.0 (12.0 to 26.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="361" pm="."><plain> Insulin 120′ (mU l−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="362" pm="."><plain>94.0 (63.0 to 138.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="363" pm="."><plain>90.0 (54.0 to 128.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="364" pm="."><plain> HOMA-IR </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="365" pm="."><plain>4.00 (2.30 to 6.36) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="366" pm="."><plain>4.85 (2.40 to 5.78) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="367" pm="."><plain> HbA1c (mmol mol−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="368" pm="."><plain>33 (31 to 34) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="369" pm="."><plain>32 (31 to 34) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="370" pm="."><plain> Cholesterol (mmol l−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="371" pm="."><plain>4.8 (3.9 to 5.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="372" pm="."><plain>4.4 (4.1 to 5.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="373" pm="."><plain> HDL (mmol l−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="374" pm="."><plain>1.10 (1.02 to 1.22) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="375" pm="."><plain>1.16 (1.03 to 1.36) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="376" pm="."><plain> LDL (mmol l−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="377" pm="."><plain>2.9 (2.3 to 3.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="378" pm="."><plain>2.4 (2.1 to 3.2) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="379" pm="."><plain> TG (mmol l−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="380" pm="."><plain>1.4 (0.9 to 1.6) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="381" pm="."><plain>1.4 (1.0 to 1.8) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="382" pm="."><plain> Total cholesterol/HDL ratio </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="383" pm="."><plain>4.3 (3.4 to 4.7) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="384" pm="."><plain>3.8 (2.7 to 5.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="385" pm="."><plain> ALT (U l−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="386" pm="."><plain>19 (15 to 26) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="387" pm="."><plain>21.5 (14.5 to 28.5) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="388" pm="."><plain> Kreatinin (μmol l−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="389" pm="."><plain>51 (48 to 55) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="390" pm="."><plain>50 (47 to 56) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="391" pm="."><plain> Vitamin B12 (pmol l−1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="392" pm="."><plain>365 (267 to 420) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="393" pm="."><plain>336 (280 to 492) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="394" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="395" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="396" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><text><SENT sid="397" pm="."><plain>Bio-impedance </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="398" pm="."><plain> Body fat (%) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="399" pm="."><plain>38.6 (36.5 to 43.2) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="400" pm="."><plain>41.2 (36.9 to 44.1)a </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="401" pm="."><plain> Fat mass (kg) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="402" pm="."><plain>31.8 (25.0 to 39.4) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="403" pm="."><plain>33.6 (27.6 to 48.5)a </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="404" pm="."><plain> Fat-free mass (kg) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="405" pm="."><plain>48.9 (45.4 to 53.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="406" pm="."><plain>50.4 (42.6 to 54.5)a </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="407" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="408" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="409" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="410" pm="."><plain>Quality of life by IWQOL-kids </plain></SENT>
</text></td><td align="center" valign="top" char="(" charoff="50"><text><SENT sid="411" pm="."><plain>n=22 </plain></SENT>
</text></td><td align="center" valign="top" char="(" charoff="50"><text><SENT sid="412" pm="."><plain>n=15 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="413" pm="."><plain> Section 1, physical comfort </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="414" pm="."><plain>83.3 (72.5 to 94.2) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="415" pm="."><plain>73.3 (63.3 to 86.7) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="416" pm="."><plain> Section 2, body esteem </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="417" pm="."><plain>75.6 (63.3 to 88.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="418" pm="."><plain>68.9 (55.6 to 84.4) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="419" pm="."><plain> Section 3, social life </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="420" pm="."><plain>86.7 (76.7 to 93.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="421" pm="."><plain>86.7 (80.0 to 90.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="422" pm="."><plain> Section 4, family relations </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="423" pm="."><plain>100 (95.8 to 100) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="424" pm="."><plain>100 (90.0 to 100) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="425" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="426" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="427" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="428" pm="."><plain>Physical fitness </plain></SENT>
</text></td><td align="center" valign="top" char="(" charoff="50"><text><SENT sid="429" pm="."><plain>n=18 </plain></SENT>
</text></td><td align="center" valign="top" char="(" charoff="50"><text><SENT sid="430" pm="."><plain>n=13 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="431" pm="."><plain> Shuttle walk test, distance in m </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="432" pm="."><plain>1500 (1138 to 1500) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="433" pm="."><plain>1500 (955 to 1500) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="434" pm="."><plain> 9 m sprint test (s) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="435" pm="."><plain>2.47 (2.35 to 2.60) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="436" pm="."><plain>2.70 (2.05 to 3.00) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="437" pm="."><plain> 10 × 5 m sprint test (s) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="438" pm="."><plain>20.63 (19.21 to 23.45) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="439" pm="."><plain>20.28 (19.15 to 22.10) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="440" pm="."><plain> Situps in 30 s (n) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="441" pm="."><plain>21 (17 to 30) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="442" pm="."><plain>17 (14 to 19) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="443" pm="."><plain> Time to stand up from supine position </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="444" pm="."><plain>2.10 (1.80 to 2.84) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="445" pm="."><plain>2.40 (1.90 to 2.96) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment for insulin resistance; IWQOL, impact of weight on quality of life; LDL, low-density lipoprotein; SDS, s.d. score; TG, triglyceride.</p></fn><fn id="t1-fn2"><p>Reported values are median (interquartile range) or numbers (%).</p></fn><fn id="t1-fn3"><label>a</label><p><italic>n</italic>=18.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tbl2"><label>Table 2</label><caption><title>Treatment effects of metformin versus placebo after 18 months</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><text><SENT sid="446" pm="."><plain>  </plain></SENT>
</text></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><text><SENT sid="447" pm="."><plain>Metformin (n=23) </plain></SENT>
</text></th><th align="center" valign="top" char="(" charoff="50"><text><SENT sid="448" pm="."><plain>ΔT=18–T=0 </plain></SENT>
</text></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><text><SENT sid="449" pm="."><plain>Placebo (n=19) </plain></SENT>
</text></th><th align="center" valign="top" char="(" charoff="50"><text><SENT sid="450" pm="."><plain>ΔT=18–T=0 </plain></SENT>
</text></th><th align="center" valign="top" char="." charoff="50"><text><SENT sid="451" pm="."><plain>Metformin versus placebo, P-value </plain></SENT>
</text></th></tr><tr><th align="left" valign="top" charoff="50"><text><SENT sid="452" pm="."><plain>  </plain></SENT>
</text></th><th align="center" valign="top" char="(" charoff="50"><text><SENT sid="453" pm="."><plain>T=0 </plain></SENT>
</text></th><th align="center" valign="top" char="(" charoff="50"><text><SENT sid="454" pm="."><plain>T=18 </plain></SENT>
</text></th><th align="center" valign="top" char="(" charoff="50"><text><SENT sid="455" pm="."><plain>  </plain></SENT>
</text></th><th align="center" valign="top" char="(" charoff="50"><text><SENT sid="456" pm="."><plain>T=0 </plain></SENT>
</text></th><th align="center" valign="top" char="(" charoff="50"><text><SENT sid="457" pm="."><plain>T=18 </plain></SENT>
</text></th><th align="center" valign="top" char="(" charoff="50"><text><SENT sid="458" pm="."><plain>  </plain></SENT>
</text></th><th align="center" valign="top" char="." charoff="50"><text><SENT sid="459" pm="."><plain>ΔT=18–T=0 </plain></SENT>
</text></th></tr></thead><tbody valign="top"><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="460" pm="."><plain>Primary outcomes </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="461" pm="."><plain> BMI </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="462" pm="."><plain>29.8 (28.1 to 34.5) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="463" pm="."><plain>29.9 (26.3 to 33.6) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="464" pm="."><plain>0.2 (−2.9 to 1.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="465" pm="."><plain>30.5 (28.7 to 38.6) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="466" pm="."><plain>32.8 (29.3 to 40.4) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="467" pm="."><plain>1.2 (−0.3 to 2.4) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="468" pm="."><plain>0.02 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="469" pm="."><plain>  BMI-SDS </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="470" pm="."><plain>3.10 (2.72 to 3.52) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="471" pm="."><plain>2.90 (2.34 to 3.39) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="472" pm="."><plain>−0.12 (−0.50 to 0.08) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="473" pm="."><plain>3.38 (3.10 to 4.20) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="474" pm="."><plain>3.29 (3.02 to 4.18) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="475" pm="."><plain>0.04 (−0.24 to 0.10) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="476" pm="."><plain>0.08 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="477" pm="."><plain> HOMA-IR </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="478" pm="."><plain>4.00 (2.30 to 6.36) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="479" pm="."><plain>3.00 (2.00 to 4.29) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="480" pm="."><plain>−1.00 (−3.17 to 2.25) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="481" pm="."><plain>4.85 (2.40 to 5.78) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="482" pm="."><plain>3.88 (2.86 to 5.56) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="483" pm="."><plain>−0.16 (−1.71 to 1.48) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="484" pm="."><plain>0.28 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="485" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="486" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="487" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="488" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="489" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="490" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="491" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="492" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="493" pm="."><plain>Other outcomes </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="494" pm="."><plain> HbA1c </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="495" pm="."><plain>33.0 (31.0 to 34.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="496" pm="."><plain>33.5 (30.8 to 34.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="497" pm="."><plain>1.0 (−1.0 to 2.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="498" pm="."><plain>32.0 (31.0 to 34.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="499" pm="."><plain>36.0 (33.0 to 37.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="500" pm="."><plain>3.0 (0.0 to 5.0) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="501" pm="."><plain>0.02 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="502" pm="."><plain> Height (cm) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="503" pm="."><plain>162.9 (159.0 to 168.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="504" pm="."><plain>166.5 (160.3 to 171.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="505" pm="."><plain>2.1 (0.5 to 6.6) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="506" pm="."><plain>162.0 (160.0 to 166.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="507" pm="."><plain>168.3 (163.7 to 171.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="508" pm="."><plain>6.2 (2.5 to 8.7) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="509" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="510" pm="."><plain> Weight (kg) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="511" pm="."><plain>82.2 (75.4 to 92.7) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="512" pm="."><plain>83.4 (76.6 to 94.2) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="513" pm="."><plain>1.6 (−4.2 to 5.9) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="514" pm="."><plain>86.1 (74.0 to 103) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="515" pm="."><plain>96.7 (79.0 to 111.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="516" pm="."><plain>12.0 (2.7 to 17.0) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="517" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="518" pm="."><plain> Bio-impedance </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="519" pm="."><plain>  </plain></SENT>
</text></td><td align="center" valign="top" char="(" charoff="50"><text><SENT sid="520" pm="."><plain>n=21 </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="521" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="522" pm="."><plain>  </plain></SENT>
</text></td><td align="center" valign="top" char="(" charoff="50"><text><SENT sid="523" pm="."><plain>n=17 </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="524" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="525" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="526" pm="."><plain>  Body fat % </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="527" pm="."><plain>38.6 (36.5 to 43.2) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="528" pm="."><plain>37.6 (30.9 to 40.9) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="529" pm="."><plain>−3.1 (−4.8 to 0.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="530" pm="."><plain>41.2 (36.9 to 44.1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="531" pm="."><plain>41.2 (37.7 to 46.9) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="532" pm="."><plain>−0.8 (−3.2 to 1.6) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="533" pm="."><plain>0.15 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="534" pm="."><plain>  Fat mass (kg) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="535" pm="."><plain>31.8 (25.0 to 39.4) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="536" pm="."><plain>31.1 (22.6 to 37.6) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="537" pm="."><plain>−0.2 (−5.2 to 2.1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="538" pm="."><plain>33.6 (27.6 to 48.5) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="539" pm="."><plain>34.9 (29.5 to 53.1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="540" pm="."><plain>2.0 (1.2 to 6.4) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="541" pm="."><plain>0.007 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="542" pm="."><plain>  Fat-free mass (kg) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="543" pm="."><plain>48.9 (45.4 to 53.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="544" pm="."><plain>49.4 (46.7 to 55.4) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="545" pm="."><plain>2.0 (−0.1 to 4.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="546" pm="."><plain>50.4 (42.6 to 54.5) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="547" pm="."><plain>52.0 (48.9 to 65.1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="548" pm="."><plain>4.5 (1.3 to 11.6) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="549" pm="."><plain>0.05 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="550" pm="."><plain> IWQOL-kids </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="551" pm="."><plain>  </plain></SENT>
</text></td><td align="center" valign="top" char="(" charoff="50"><text><SENT sid="552" pm="."><plain>n=17 </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="553" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="554" pm="."><plain>  </plain></SENT>
</text></td><td align="center" valign="top" char="(" charoff="50"><text><SENT sid="555" pm="."><plain>n=12 </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="556" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="557" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="558" pm="."><plain>  Total score </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="559" pm="."><plain>83.0 (76.7 to 91.9) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="560" pm="."><plain>90.0 (81.5 to 98.1) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="561" pm="."><plain>2.6 (0.2 to 5.7) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="562" pm="."><plain>80.0 (72.6 to 85.2) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="563" pm="."><plain>84.8 (77.8 to 90.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="564" pm="."><plain>5.2 (−2.2 to 9.6) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="565" pm="."><plain>0.94 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="566" pm="."><plain>  Section 1 </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="567" pm="."><plain>83.3 (72.5 to 94.2) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="568" pm="."><plain>91.7 (79.2 to 100) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="569" pm="."><plain>6.7 (0 to 13.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="570" pm="."><plain>73.3 (63.3 to 86.7) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="571" pm="."><plain>90.0 (76.7 to 93.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="572" pm="."><plain>6.7 (3.3 to 21.7) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="573" pm="."><plain>0.41 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="574" pm="."><plain>  Section 2 </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="575" pm="."><plain>75.6 (63.3 to 88.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="576" pm="."><plain>82.2 (66.1 to 94.4) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="577" pm="."><plain>2.2 (−2.2 to 5.6) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="578" pm="."><plain>68.9 (55.6 to 84.4) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="579" pm="."><plain>73.3 (67.8 to 87.8) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="580" pm="."><plain>5.6 (−3.9 to 10.6) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="581" pm="."><plain>0.66 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="582" pm="."><plain>  Section 3 </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="583" pm="."><plain>86.7 (76.7 to 93.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="584" pm="."><plain>95.0 (86.7 to 99.2) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="585" pm="."><plain>3.3 (0 to 6.7) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="586" pm="."><plain>86.7 (80.0 to 90.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="587" pm="."><plain>90.0 (86.7 to 95.0) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="588" pm="."><plain>0 (−6.7 to 6.7) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="589" pm="."><plain>0.25 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="590" pm="."><plain>  Section 4 </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="591" pm="."><plain>100 (95.8 to 100) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="592" pm="."><plain>100 (95.8 to 100) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="593" pm="."><plain>0 (0 to 3.3) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="594" pm="."><plain>100 (90.0 to 100) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="595" pm="."><plain>100 (95.0 to 100) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="596" pm="."><plain>0 (0 to 5.8) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="597" pm="."><plain>0.86 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="598" pm="."><plain> Fitness test </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="599" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="600" pm="."><plain>  </plain></SENT>
</text></td><td align="center" valign="top" char="(" charoff="50"><text><SENT sid="601" pm="."><plain>n=15 </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="602" pm="."><plain>  </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="603" pm="."><plain>  </plain></SENT>
</text></td><td align="center" valign="top" char="(" charoff="50"><text><SENT sid="604" pm="."><plain>n=7 </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="605" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="606" pm="."><plain>  Shuttle walk test (m) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="607" pm="."><plain>1500 (1163 to 1500) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="608" pm="."><plain>1500 (1415 to 1500) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="609" pm="."><plain>0 (0 to 120) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="610" pm="."><plain>1180 (850 to 1500) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="611" pm="."><plain>1360 (1170 to 1500) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="612" pm="."><plain>270 (−100 to 320) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="613" pm="."><plain>0.52 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="614" pm="."><plain>  9 m sprint (s) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="615" pm="."><plain>2.48 (2.40 to 2.65) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="616" pm="."><plain>2.53 (2.38 to 2.71) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="617" pm="."><plain>0.01 (−0.14 to 0.12) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="618" pm="."><plain>2.70 (2.00 to 3.09) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="619" pm="."><plain>2.60 (2.47 to 3.04) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="620" pm="."><plain>0.08 (−0.37 to 0.58) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="621" pm="."><plain>0.46 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="622" pm="."><plain>  10 × 5 m sprint (s) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="623" pm="."><plain>20.63 (19.21 to 23.44) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="624" pm="."><plain>20.58 (19.14 to 21.46) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="625" pm="."><plain>−0.40 (−2.30 to 0.60) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="626" pm="."><plain>21.00 (20.00 to 25.53) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="627" pm="."><plain>21.10 (20.53 to 24.03) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="628" pm="."><plain>−0.10 (−0.60 to 0.53) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="629" pm="."><plain>0.46 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="630" pm="."><plain> Situps in 30 s (n) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="631" pm="."><plain>21 (17 to 30) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="632" pm="."><plain>24 (19 to 30) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="633" pm="."><plain>0 (−11 to 8) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="634" pm="."><plain>17 (14 to 19) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="635" pm="."><plain>23 (19 to 25) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="636" pm="."><plain>5 (4 to 11) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="637" pm="."><plain>0.33 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="638" pm="."><plain>  Time to stand up from supine position (s) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="639" pm="."><plain>2.10 (1.80 to 2.84) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="640" pm="."><plain>2.31 (2.13 to 2.58) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="641" pm="."><plain>−0.05 (−0.33 to 0.61) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="642" pm="."><plain>2.40 (1.90 to 2.96) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="643" pm="."><plain>2.88 (2.26 to 2.93) </plain></SENT>
</text></td><td align="char" valign="top" char="(" charoff="50"><text><SENT sid="644" pm="."><plain>−0.03 (−0.32 to 1.24) </plain></SENT>
</text></td><td align="char" valign="top" char="." charoff="50"><text><SENT sid="645" pm="."><plain>0.49 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: BMI, body mass index; HOMA-IR, homeostasis model assessment for insulin resistance; IWQOL, impact of weight on quality of life; SDS, s.d. score.</p></fn><fn id="t2-fn2"><p>All values are median (interquartile range). Bold entries are used for <italic>P</italic>-values which were below the significance level of &lt;0.05.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tbl3"><label>Table 3</label><caption><title>Safety and tolerability of metformin versus placebo</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><text><SENT sid="646" pm="."><plain>  </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="647" pm="."><plain>Metformin (n=23) </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="648" pm="."><plain>Placebo (n=19) </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="649" pm="."><plain>P-value </plain></SENT>
</text></th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50"><text><SENT sid="650" pm="."><plain>Safety, n (%) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="651" pm="."><plain> ALT &gt;69 U l−1 (girls) or &gt;78 U l−1 (boys) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="652" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="653" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="654" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="655" pm="."><plain> GFR &lt;60 ml min−1 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="656" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="657" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="658" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="659" pm="."><plain> Vitamin B12 &lt;140 pmol l−1 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="660" pm="."><plain>3 (13.0) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="661" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="662" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="663" pm="."><plain>  </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="664" pm="."><plain>  </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="665" pm="."><plain>  </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="666" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><text><SENT sid="667" pm="."><plain>Tolerability Adverse events, n (%) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="668" pm="."><plain> Nausea </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="669" pm="."><plain>17 (73.9) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="670" pm="."><plain>8 (42.1) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="671" pm="."><plain>0.04 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="672" pm="."><plain> Diarrhoea </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="673" pm="."><plain>14 (60.9) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="674" pm="."><plain>9 (47.4) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="675" pm="."><plain>0.38 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: ALT, alanine aminotransferase; GFR, glomerular filtration rate; NA, not applicable. Bold entry is used for <italic>P</italic>-value which were below the significance level of &lt;0.05.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
